ALG advise Felix Pharmaceuticals on a $175m growth private equity investment

ALG is delighted to have advised its long-standing client, Dublin headquartered companion animal healthcare company Felix Pharmaceuticals on a $175m growth private equity investment by Advent International, who will take up a minority stake in Felix Pharmaceuticals through a combination of primary and secondary share acquisition. The ALG team was led by Stephen Quinlivan, Corporate Partner and also featured Catherine Mannix, Corporate Associate, Miah Phelan Sweeney and Daniel O’Boyle, Corporate Solicitors.

Stephen Quinlivan commented “We are thrilled to have advised and supported our long-standing client, Felix Pharmaceuticals on this watershed transaction, that will help position Felix as the leading generics player for companion pets worldwide. We have been advising Neeraj and the team at Felix since its Series A investment back in 2015 and look forward to working with them on this exciting next stage of growth and development”.

Read more here.

For further information in relation to ALG's Life Sciences offering, please click here.

Date published: 9 June 2025